Business
Summary of Capital Markets Day
Summary of Capital Markets Day.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 2482E Avacta Group PLC 08 February 2018 \n\n \n \n \n \n \n \n8 February 2018\n \nAvacta Group plc\n \n(\"Avacta\" or \"the Group\" or \"the Company\")\n \nCapital Markets Day\nStrong Progress and Milestones Outlined to 2021\n \nAvacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to provide a review of progress against the objectives set in 2015 that were outlined at its Capital Markets Day, which took place on 7 February 2018 for financial analysts and institutional investors. The Group outlined the milestones that it expects to achieve over the next few years as it aims to build a clinical phase pipeline of Affimer therapeutics and a recurring revenue stream from Affimer reagents. \n \nDuring the presentation, Dr Alastair Smith, Chief Executive Officer, reviewed the size of the opportunity presented by the Affimer technology in the life sciences markets and reiterated the two focal points of the Avacta business model: to build a reagents business in non-therapeutic markets with long term recurring revenue and to grow a pipeline of Affimer therapeutics for development in-house and partnering. \n \nDr Smith further reviewed the excellent progress that the Group has made against all the objectives set out in 2015, namely:\n \n1) Developing the first Affimer therapeutic candidate for clinical development\n2) Building a pipeline of therapeutic Affimers and enabling Affimer platform technologies for licensing or future in-house development\n3) Securing further Affimer therapeutic license/partnering deals\n4) Growing a custom Affimer revenue stream with the potential for long-term royalties.\n \nAvacta has developed a large number of lead Affimer molecules in its first programme, a PD-L1 antagonist, and is on track to make an IND filing in 2019/2020 and to begin phase 1 clinical trials in 2020. Dr Smith pointed out that the immuno-oncology field is focusing on combination therapies and that the PD-L1 assets that have been developed to date provide a backbone for future combinations with, for example, LAG-3 inhibitors, which the Group is also developing. \n \nThe Group has now established a pipeline of ten disc...